| 证券代码：603809 | 证券简称：豪能股份 | 公告编号：2025-057 | | --- | --- | --- | | | 转债 | | | 转债代码：113690 | 转债简称：豪 24 | | 成都豪能科技股份有限公司 关于实施"豪 24 转债"赎回暨摘牌的 第二次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2025 年 9 月 23 日收市后，距离 9 月 29 日（"豪 24 转债"最后交易日）仅 剩 4 个交易日，9 月 29 日为"豪 24 转债"最后一个交易日。 最后转股日：2025 年 10 月 10 日 截至 2025 年 9 月 23 日收市后，距离 10 月 10 日（"豪 24 转债"最后转股日）仅 剩 7 个交易日，10 月 10 日为"豪 24 转债"最后一个转股日。 成都豪能科技股份有限公司（以下简称"公司"）的股票自 2025 年 8 月 25 日 至 2025 年 9 月 12 日连续三十个交易日内有十五个交易日收盘价格不低于"豪 24 转债" ...

Core Viewpoint - The company has developed a series of high-precision planetary gear reducers and new types of cycloidal gear reducers, and is engaging in business exchanges and collaborations with multiple companies in the fields of humanoid robots, robotic dogs, exoskeletons, and dexterous hands, with some products already achieving mass supply [1] Group 1 - The company has developed high-precision planetary gear reducers [1] - The company has developed new types of cycloidal gear reducers [1] - The company is collaborating with multiple firms in various advanced robotics fields [1] Group 2 - The company has achieved mass supply of some of its products [1]

Core Points - The company is implementing the early redemption of the "Hao 24 Convertible Bonds" and will delist them from the Shanghai Stock Exchange starting October 13, 2025 [4][15]. Summary by Sections Redemption Details - The last trading day for the "Hao 24 Convertible Bonds" is September 29, 2025, and the last conversion day is October 10, 2025 [2][3]. - The redemption price is set at 100.1945 CNY per bond, which includes accrued interest [8][10]. - The redemption registration date is October 10, 2025, and the redemption payment date is October 13, 2025 [6][14]. Conditions for Redemption - The company has triggered the conditional redemption clause as the stock price was above 130% of the conversion price for 15 out of 30 trading days from August 25 to September 12, 2025 [5][7]. - The company has the right to redeem all or part of the unconverted bonds if the remaining balance is less than 30 million CNY [7]. Investor Guidance - Investors are advised to convert or sell their bonds within the specified time frame to avoid forced redemption, which could lead to significant investment losses [4][17]. - The current market price of the bonds is significantly higher than the redemption price, indicating potential losses for investors who do not act in time [17].

| 证券代码：603809 | 证券简称：豪能股份 | 公告编号：2025-056 | | --- | --- | --- | | | 转债 | | | 转债代码：113690 | 转债简称：豪 24 | | 成都豪能科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于实施"豪 24 转债"赎回暨摘牌的 重要内容提示： 第一次提示性公告 截至 2025 年 9 月 22 日收市后，距离 9 月 29 日（"豪 24 转债"最后交易日）仅 剩 5 个交易日，9 月 29 日为"豪 24 转债"最后一个交易日。 最后转股日：2025 年 10 月 10 日 截至 2025 年 9 月 22 日收市后，距离 10 月 10 日（"豪 24 转债"最后转股日）仅 剩 8 个交易日，10 月 10 日为"豪 24 转债"最后一个转股日。 成都豪能科技股份有限公司（以下简称"公司"）的股票自 2025 年 8 月 25 日 至 2025 年 9 月 12 日连续三十个交易日内有十五个交易日收盘价格不低于"豪 24 转债" ...

| 证券代码：603809 | 证券简称：豪能股份 公告编号：2025-055 | | --- | --- | | 转债代码：113690 | 转债简称：豪 转债 24 | 成都豪能科技股份有限公司 关于实施"豪 24 转债"赎回暨摘牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 最后转股日：2025 年 10 月 10 日 证券停复牌情况：适用 因提前赎回"豪 24 转债"，本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | | 停复牌类型 | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 113690 | 豪 24 | 转债 | 可转债债券停牌 | 2025/9/30 | | | | 截至 2025 年 9 月 19 日收市后，距离 9 月 29 日（"豪 24 转债"最后交易日）仅 剩 6 个交易日，9 月 29 日为"豪 24 转债"最后一个交易日。 截至 2025 ...

Group 1: Company Overview - Lepu Medical - Lepu Medical is a leading cardiovascular company in China, with a diverse product matrix. In H1 2025, the company achieved revenue of 3.369 billion yuan, a year-on-year decrease of 0.43%, and a net profit of 691 million yuan, down 0.91% year-on-year [3] - The company is strategically expanding into innovative drugs for cardiovascular and metabolic diseases through its subsidiary, Minwei Biotech, which focuses on obesity and type 2 diabetes treatments. As of August 2025, several products are in various clinical trial phases [3] - Lepu Medical is also actively developing its aesthetic medicine segment, with new products like dermal fillers and hyaluronic acid injections receiving approval, indicating strong growth potential in the non-medical insurance market [3] Group 2: Company Overview - Superwin International Holdings - Superwin International Holdings has over 20 years of experience in elastic fabric, with a stable management team. The company generates 55.4% of its revenue from sports fabrics and is well-positioned to capture more orders due to its mature overseas production capacity [6][7] - The company is expected to see net profits of 590 million, 640 million, and 700 million HKD from 2025 to 2027, benefiting from a rebalancing of supply and demand and moderate raw material prices [5][6] - Superwin has maintained a stable dividend payout ratio of around 50%, with a dividend yield exceeding 9% for the past four years, making it an attractive investment opportunity [8] Group 3: Industry Insights - Biopharmaceuticals - The biopharmaceutical industry is witnessing a shift towards innovative drug development, particularly in cardiovascular and metabolic diseases, driven by companies like Lepu Medical [3] - The market for aesthetic medicine is expanding, with increasing regulatory approvals for new products, indicating a growing consumer demand for non-traditional medical treatments [3] Group 4: Industry Insights - Textile and Apparel - The sportswear segment is outpacing other apparel categories, with rising demand for elastic, breathable, and antibacterial fabrics benefiting suppliers like Superwin International [8] - The company is positioned to leverage its established relationships with major sports brands, which have been in collaboration for over five years, ensuring a steady flow of orders [8]

Core Points - The stock of Haoneng Co., Ltd. dropped by 5.33% on September 19, closing at 15.80 CNY per share with a trading volume of 327 million CNY and a turnover rate of 2.36%, resulting in a total market capitalization of 13.586 billion CNY [1] Company Overview - Haoneng Co., Ltd. is located in Chengdu Economic and Technological Development Zone, Sichuan Province, and was established on September 25, 2006, with its listing date on November 28, 2017 [1] - The company's main business involves the research, production, and sales of synchronizer components for automotive transmissions [1] Revenue Composition - The revenue composition of Haoneng Co., Ltd. is as follows: synchronizers account for 48.89%, differentials for 21.21%, other components for 14.50%, aerospace parts for 13.22%, and supplementary items for 2.19% [1] Fund Holdings - Manulife Fund has a significant holding in Haoneng Co., Ltd., with its Manulife Efficient Selection Mixed Fund (LOF) holding 1.6252 million shares, representing 6.42% of the fund's net value, making it the third-largest holding [2] - The fund has reported a floating loss of approximately 1.4464 million CNY as of the latest update [2] Fund Performance - The Manulife Efficient Selection Mixed Fund (LOF) was established on May 12, 2006, with a current size of 387 million CNY, achieving a year-to-date return of 17.64% and a one-year return of 36.65% [2] - Since its inception, the fund has generated a return of 282.07%, with the fund manager, Wu Hua, having a tenure of 11 years and 182 days [2]

Core Points - Chengdu Haoneng Technology Co., Ltd. has approved a bank credit limit application totaling RMB 420 million for 2025, which was authorized by the shareholders' meeting [2] - The company has signed a working capital loan contract with Bank of China Chengdu Jinjing Branch for RMB 50 million with a term of 24 months [3] - The company has cumulative bank credit applications amounting to RMB 3.314 billion, with an unused credit limit of RMB 886 million as of the announcement date [6][7] Credit and Guarantee Details - The company has pledged 100% equity of Chengdu Haoyiqiang Aviation Equipment Manufacturing Co., Ltd. as collateral for the credit, with a maximum guarantee amount of RMB 279.3025 million [4] - The company has also provided guarantees for its subsidiaries, including a maximum liability guarantee of RMB 30 million for Chengdu Haoyiqiang [10] - The total amount of external guarantees provided by the company is RMB 2.332 billion, accounting for 77.11% of the audited net assets for 2024, with no overdue guarantees reported [11] Impact on Company - The credit application is aimed at meeting the daily operational liquidity needs of the company and its subsidiaries, enhancing financial security, and supporting sustainable development [7] - The board of directors believes that the guarantees provided will not harm the interests of the company and its shareholders, and the subsidiaries have stable operations and good credit status [10]

证券日报网讯 9月18日晚间，豪能股份发布公告称，截至本公告披露日，公司对外担保总额为人民币 23.32亿元，占公司2024年度经审计净资产的77.11%，均为对子公司提供的担保，无逾期担保。 （文章来源：证券日报） ...

关于 2025 年度向银行申请授信额度的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 3 月 21 日，成都豪能科技股份有限公司（以下简称"公司"）召开第六 届董事会第十一次会议，审议通过了《关于 2025 年度向银行申请授信额度的议案》， 并经 2025 年 4 月 11 日召开的 2024 年年度股东大会批准，同意公司及子公司向银行 申请总额不超过人民币 420,000.00 万元的授信额度（在不超过总授信额度范围内， 最终以各银行实际审批的授信额度为准）。本次向银行申请授信额度授权期限为公司 2024 年年度股东大会审议通过之日起至 2025 年年度股东大会召开之日止。上述授信 额度仅由公司及子公司使用，授信期限内，授信额度可循环使用。具体内容请详见 2025 年 3 月 22 日刊载于上海证券交易所网站（www.sse.com.cn）及公司指定信息披 露媒体的《关于 2025 年度向银行申请授信额度的公告》（公告编号：2025-013）。 一、本次授信情况概述 | 证券代码：603809 | ...